TABLE 2.
Progression‐free survival and overall survival in the TCGA groups of uterine carcinosarcoma, using the p53abn group as reference
| TCGA group (UCS) | Progression‐free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| POLEmut | NV | NV | NV | NV | NV | NV |
| MMRd | 0.19 | 0.08–0.46 | <0.001 | 0.91 | 0.44–1.87 | 0.788 |
| NSMP | 1.02 | 0.59–1.78 | 0.936 | 1.51 | 0.76–2.99 | 0.240 |
| p53abn (reference) | 1.00 | — | — | 1.00 | — | — |
Abbreviations: CI, confidence interval; HR, hazard ratio; UCS, uterine carcinosarcoma.
a
NV, not evaluable, because no event occurred in POLEmut cases.